MPLT — MapLight Therapeutics, Inc.
Is MPLT overbought or oversold? Here is the current MarketMoodz read.
MapLight Therapeutics, Inc. (MPLT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $6.90. The rating moved from Strong Oversold to Oversold on November 10, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$6.90
- Last changeMoved from Strong Oversold to Oversold on November 10, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
MapLight Therapeutics, Inc. (MPLT) displays mixed signals: a materially negative 10-Q and limited filing comparables increase uncertainty around financial health and near-term liquidity, while recent 8-Ks indicate intermittent operational developments. Macro market tone is constructive but favors large-cap pharma, limiting sector tailwinds for a small-cap biotech. Primary near-term drivers will be cash runway/funding decisions, any upcoming clinical or commercial announcements, and investor reactions to additional filings. Scenarios range from modest upside if positive event execution or partnerships occur, to dilution and downside if financing or regulatory setbacks materialize.
Key factors
- Recent 10-Q flagged issues and negative sentiment in filings indicating near-term operational or financial stress
- Two 8-Ks including one positive development — suggests intermittent corporate activity but unclear material impact
- Limited EDGAR comparatives available, reducing transparency for trend analysis
- Sector-wide pressure on small/mid-cap diagnostics & biotech from convertible-debt and dilution dynamics
- Broader market risk-on tone supports growth names generally, but flows are favoring large-cap pharma over small-cap biotechs
- Retail chatter showing some optimism around upcoming releases, which could provide short-term event-driven volatility
Risks
- Cash runway and liquidity constraints leading to fundraising needs or dilutive financing
- Regulatory or clinical setbacks that could delay product timelines or approvals
- Management execution and commercialization risk for any near-term product launches
- Competitive pressure from larger incumbents and faster-moving device/pharma entrants
- Market-driven volatility and sector rotation away from small-cap biotech names
- Limited public disclosure and sparse financial comparables increasing investor uncertainty
See today's live rating, score and targets
Members see the live hourly rating for MPLT — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.